<DOC>
	<DOC>NCT01063036</DOC>
	<brief_summary>The purpose of this study is to show that the combination of entecavir and tenofovir, is effective and well tolerated in chronic hepatitis B patients who have failed previous treatment.</brief_summary>
	<brief_title>Efficacy and Safety Study of Entecavir Plus Tenofovir in Patients With Chronic Hepatitis B Who Failed Previous Treatment</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B, Chronic</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Subjects with chronic hepatitis B virus (HBV) infection; either hepatitis Be antigen(HBeAg)negative or HBeAgpositive Subjects must have a treatment failure to their current nucleoside/ nucleotide treatment regimen Prior entecavir and/or tenofovir monotherapy is allowed Subjects must have compensated liver function Women who are pregnant or breastfeeding Evidence of decompensated cirrhosis Coinfection with HIV, hepatitis C virus (HCV), or hepatitis D virus (HDV) Moderate or severe renal impairment Recent history of pancreatitis Therapy with interferon, thymosin alpha or other immunostimulators within 24 weeks of being assigned to study drug into this study Prior entecavir/tenofovir combination therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>